Who is sponsoring NCT00866047?

NCT00866047 is sponsored by Seagen Inc..

What condition does NCT00866047 study?

NCT00866047 studies Lymphoma, Large-Cell, Anaplastic, Lymphoma, Non-Hodgkin.

What drugs are being tested in NCT00866047?

Interventions: brentuximab vedotin.

What is the status of NCT00866047?

NCT00866047 is currently COMPLETED.

Last reviewed 2017-02-02 · How we verify

A Phase 2 Study of SGN-35 in Treatment of Patients With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma (ALCL)

NCT00866047 Phase 2 COMPLETED Results posted

This is a single-arm, open-label, multicenter, clinical trial to evaluate the efficacy and safety of brentuximab vedotin (SGN-35) as a single agent in patients with relapsed or refractory ALCL.

Details

Lead sponsor	Seagen Inc.
Phase	Phase 2
Status	COMPLETED
Enrolment	58
Start date	2009-03
Completion	2016-06

Conditions

Lymphoma, Large-Cell, Anaplastic
Lymphoma, Non-Hodgkin

Interventions

brentuximab vedotin

Primary outcomes

Objective Response Rate by Independent Review Group — up to 12 months
Percentage of participants who achieved a best response of complete remission (CR, disappearance of all evidence of disease) or partial remission (PR, regression of greater than or equal to 50% of measurable disease and no new sites) per Cheson 2007 Revised Response Criteria for Malignant Lymphoma.

Countries

United States, Belgium, Canada, France, United Kingdom